Skip to main content
NCBI home page
Cellular and Molecular Neurobiology logoLink to Cellular and Molecular Neurobiology
. 1999 Aug;19(4):511–532. doi: 10.1023/A:1006990925122

Metabolism and Excretion of Mood Stabilizers and New Anticonvulsants

Terence A Ketter 1,✉, Mark A Frye 2, Gabriela Corá-Locatelli 2, Timothy A Kimbrell 2, Robert M Post 2
PMCID: PMC11545531  PMID: 10379423

Abstract

1. The mood stabilizers lithium, carbamazepine (CBZ), and valproate (VPA), have differing pharmacokinetics, structures, mechanisms of action, efficacy spectra, and adverse effects. Lithium has a low therapeutic index and is renally excreted and hence has renally-mediated but not hepatically-mediated drug–drug interactions.

2. CBZ has multiple problematic drug–drug interactions due to its low therapeutic index, metabolism primarily by a single isoform (CYP3A3/4), active epoxide metabolite, susceptibility to CYP3A3/4 or epoxide hydrolase inhibitors, and ability to induce drug metabolism (via both cytochrome P450 oxidation and conjugation). In contrast, VPA has less prominent neurotoxicity and three principal metabolic pathways, rendering it less susceptible to toxicity due to inhibition of its metabolism. However, VPA can increase plasma concentrations of some drugs by inhibiting metabolism and increase free fractions of certain medications by displacing them from plasma proteins.

3. Older anticonvulsants such as phenobarbital and phenytoin induce hepatic metabolism, may produce toxicity due to inhibition of their metabolism, and have not gained general acceptance in the treatment of primary psychiatric disorders.

4. The newer anticonvulsants felbamate, lamotrigine, topiramate, and tiagabine have different hepatically-mediated drug–drug interactions, while the renally excreted gabapentin lacks hepatic drug–drug interactions but may have reduced bioavailability at higher doses.

5. Investigational anticonvulsants such as oxcarbazepine, vigabatrin, and zonisamide appear to have improved pharmacokinetic profiles compared to older agents.

6. Thus, several of the newer anticonvulsants lack the problematic drug-drug interactions seen with older agents, and some may even (based on their mechanisms of action and preliminary preclinical and clinical data) ultimately prove to have novel psychotropic effects.

Keywords: bipolar disorder, mood disorders, metabolism, excretion, drug–drug interactions, mood stabilizers, anticonvulsants, lithium, carbamazepine, valproate, felbamate, gabapentin, lamotrigine, topiramate, tiagabine

REFERENCES

  1. Albani, F., Riva, R., and Baruzzi, A. (1993). Clarithromycin-carbamazepine interaction: A case report. Epilepsia34:161–162. [DOI] [PubMed] [Google Scholar]
  2. Andersen, B. B., Mikkelsen, M., Vesterager, A., Dam, M., Kristensen, H. B., Pedersen, B., Lund, J., and Mengel, H. (1991). No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res.10:201–204. [DOI] [PubMed] [Google Scholar]
  3. Arana, G. W., Epstein, S., Molloy, M., and Greenblatt, D. J. (1988). Carbamazepine-induced reduction of plasma alprazolam concentrations: a clinical case report. J. Clin. Psychiatry49:448–449. [PubMed] [Google Scholar]
  4. Ashton, A. K., and Wolin, R. E. (1996). Nefazodone-induced carbamazepine toxicity [letter]. Am. J. Psychiatry153:733. [DOI] [PubMed] [Google Scholar]
  5. Bachmann, K. A., and Jauregui, L. (1993). Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica23:307–315. [DOI] [PubMed] [Google Scholar]
  6. Baruzzi, A., Albani, F., and Riva, R. (1994). Oxcarbazepine: Pharmacokinetic interactions and their clinical relevance. Epilepsia35 (Suppl. 3):S14-S19. [DOI] [PubMed] [Google Scholar]
  7. Borchert, L. D. (1996). Exercise-induced exacerbation of partial seizures due to enhanced gabapentin clearance. Annual Meeting of the American Epilepsy Society, San Francisco, December 7–10, 1996. Epilepsia37 (Suppl. 5):158 (Abstract 6.26). [Google Scholar]
  8. Bourgeois, B. F. (1988). Pharmacologic interactions between valproate and other drugs. Am. J. Med.84:29–33. [DOI] [PubMed] [Google Scholar]
  9. Bourgeois, B. F. (1996). Drug interaction profile of topiramate. Epilepsia37 (Suppl. 2):S14-S17. [DOI] [PubMed] [Google Scholar]
  10. Bowden, C. L., Brugger, A. M., Swann, A. C., Calabrese, J. R., Janicak, P. G., Petty, F., Dilsaver, S. C., Davis, J. M., Rush, A. J., Small, J. G., Garza-Trevino, E. S., Risch, S. C., Goodnick, P. J., and Morris, D. D. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA271:918–924. [PubMed] [Google Scholar]
  11. Bowden, C. L., Janicak, P. G., Orsulak, P., Swann, A. C., Davis, J. M., Calabrese, J. R., Goodnick, P., Small, J. G., Rush, A. J., Kimmel, S. E., Risch, S. C., and Morris, D. D. (1996). Relation of serum valproate concentration to response in mania. Am. J. Psychiatry153:765–770. [DOI] [PubMed] [Google Scholar]
  12. Brodie, M. J. (1995). Tiagabine pharmacology in profile. Epilepsia36 (Suppl. 6):S7-S9. [DOI] [PubMed] [Google Scholar]
  13. Brodie, M. J., and MacPhee, G. J. (1986). Carbamazepine neurotoxicity precipitated by diltiazem. Br. Med. J.292:1170–1171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Buchanan, R. A., Page, J. G., French, J. A., Leppik, I. E., and Padgett, C. S. (1997a). Prediction of zonisamide drug interactions based on metabolic isozymes. Annual Meeting of the American Epilepsy Society. Boston. December 7–10, 1997. Epilepsia38 (Suppl. 8):108 (Abstract 3.078). [Google Scholar]
  15. Buchanan, R. A., Page, J. G., French, J. A., Leppik, I. E., and Padgett, C. S. (1997b). Zonisamide drug interactions. Annual Meeting of the American Epilepsy Society. Boston. December 7–10, 1997. Epilepsia38 (Suppl. 8):107 (Abstract 3.075). [Google Scholar]
  16. Calabrese, J. R. (1996). Lamotrigine in treatment refractory manic depression. 20th Congress of Collegium Internationale Neuro-Psychopharmacologicum. Melbourne, June 23–27, 1996. Eur. Neuropsychopharmacol.6 (Suppl. 3):98.(Abstract S–36–4). [PubMed] [Google Scholar]
  17. Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., and Rudd, D. (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J. Clin. Psychiatry60:79–88. [DOI] [PubMed] [Google Scholar]
  18. Calabrese, J. R., Shelton, M. D., III, Keck, P. E., Jr., McElroy, S. L., and Werkner, J. E. (1998). Topiramate in severe treatment-refractory mania. 151st Annual Meeting of the American Psychiatric Association, Toronto, May 30–June 4, 1998. Abstract NR202. pp. 121–122.
  19. Capewell, S., Freestone, S., Critchley, J. A., Pottage, A., and Prescott, L. F. (1988). Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet2:480–482. [DOI] [PubMed] [Google Scholar]
  20. Carwile, S. T., Husain, A. M., Miller, P. P., and Radtke, R. A. (1997). Lamotrigine and sexual dysfunction in male patients with epilepsy. Annual Meeting of the American Epilepsy Society, Boston, December 7–10, 1997. Epilepsia38 (Suppl. 8):180 (Abstract 5.040). [Google Scholar]
  21. Charles, C. L., Stoesz, L., and Tollefson, G. (1990). Zonisamide-induced mania. Psychosomatics31:214–217. [DOI] [PubMed] [Google Scholar]
  22. Critchley, M. A. E. (1994). Effects of lamotrigine (Lamictal) in an animal model of anxiety. Br. J. Pharmacol.111:205P (abstract).8012697 [Google Scholar]
  23. Crockatt, J. G., Greiner, M., Clift, L. L., and Pande, A. C. (1998). Treatment of panic disorder with gabapentin. 38th Annual Meeting of the New Clinical Drug Evaluation Unit Program, Boca Raton, June 10–13, 1998. Abstract. p. 154.
  24. de Leon, J., and Bork, J. (1997). Risperidone and cytochrome P450 3A [letter]. J. Clin. Psychiatry58:450. [DOI] [PubMed] [Google Scholar]
  25. Denbow, C. E., and Fraser, H. S. (1990). Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South. Med. J.83:981. [DOI] [PubMed] [Google Scholar]
  26. Dichter, M. A., and Brodie, M. J. (1996). New antiepileptic drugs. N. Engl. J. Med.334:1583–1590. [DOI] [PubMed] [Google Scholar]
  27. Dimond, K. R., Pande, A. C., Lamoreaux, L., and Pierce, M. W. (1996). Effect of gabapentin (Neurotonin) on mood and well-being in patients with epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry20:407–417. [DOI] [PubMed] [Google Scholar]
  28. Eichelbaum, M., Tomson, T., Tybring, G., and Bertilsson, L. (1985). Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin. Pharmacokinet.10:80–90. [DOI] [PubMed] [Google Scholar]
  29. Eke, T., Talbot, J. F., and Lawden, M. C. (1997). Severe persistent visual field constriction associated with vigabatrin. BMJ314:180–181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Emrich, H. M. (1990). Studies with (Trileptal) oxcarbazepine in acute mania. Int. Clin. Psychopharmacol.5:83–88.1696292 [Google Scholar]
  31. Ereshefsky, L., Jann, M. W., Saklad, S. R., and Davis, C. M. (1986). Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview. J. Clin. Psychiatry47:6–15. [PubMed] [Google Scholar]
  32. Faigle, J. W., and Feldmann, K. F. (1995). Carbamazepine: Chemistry and biotransformation. In Levy, R. H., Mattson, R. H., and Meldrum, B. S. (eds.), Antiepileptic Drugs, 4th ed., Raven Press, New York, pp. 499–513. [Google Scholar]
  33. Forsythe, W. I., Owens, J. R., and Toothill, C. (1981). Effectiveness of acetazolamide in the treatment of carbamazepine-resistant epilepsy in children. Dev. Med. Child. Neurol.23:761–769. [DOI] [PubMed] [Google Scholar]
  34. Fritze, J., Unsorg, B., and Lanczik, M. (1991). Interaction between carbamazepine and fluvoxamine. Acta Psychiatr. Scand.84:583–584. [DOI] [PubMed] [Google Scholar]
  35. Frye, M. A., Ketter, T. A., Osuch, E. A., Kimbrell, T., Speer, A. M., Dunn, R. T., and Post, R. M. (1998a). Gabapentin and lamotrigine monotherapy in mood disorder: an update. 151st Annual Meeting of the American Psychiatric Association, Toronto, May 30–June 4, 1998a. Symposium 77D. p. 150.
  36. Frye, M. A., Kimbrell, T. A., Dunn, R. T., Piscitelli, S., Grothe, D., Vanderham, E., Corá-Locatelli, G., Post, R. M., and Ketter, T. A. (1998b). Gabapentin does not alter single-dose lithium pharmacokinetics. J. Clin. Psychopharmacol.18:461–464. [DOI] [PubMed] [Google Scholar]
  37. Garland Bunney, B., Bunney, W. E., Jr., and Carlsson, A. (1995). Schizophrenia and glutamate. In Bloom, F. E. and Kupfer, D. J. (eds.), Psychopharmacology: The Fourth Generation of Progress, Raven, New York, pp. 1205–1214. [Google Scholar]
  38. Garnett, W. R., Levy, B., McLean, A. M., Zhang, Y., Couch, R. A., Rudnic, E. M., Pellock, J. M., and Belendiuk, G. W. (1998). Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia39:274–279. [DOI] [PubMed] [Google Scholar]
  39. Gidal, B. E., Anderson, G. D., Spencer, N. W., Maly, M., Murty, J., Pitterle, M., and Collins, M. (1994). Valproic acid (VPA) associated weight gain in monotherapy patients with epilepsy. Annual Meeting of the American Epilepsy Society, New Orleans, December 2–8, 1994. Epilepsia35 (Suppl. 8):142 (Abstract L.03). [Google Scholar]
  40. Gidal, B. E., Lensmeyer, G. L., and Pitterle, M. E. (1997). In vitro characterization of topiramate (TPM) binding to erythrocyte (RBCs): potential impact on therapeutic drug monitoring. Annual Meeting of the American Epilepsy Society, Boston, December 7–10, 1997. Epilepsia38 (Suppl. 8):98 (Abstract 3.036). [Google Scholar]
  41. Gisclon, L. G., Curtin, C. R., Kramer, L. D., Sachdeo, R. C., and Levy, R. H. (1994). The steady-state (SS) pharmacokinetics of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy. Annual Meeting of the American Epilepsy Society, New Orleans, December 2–8, 1994. Epilepsia35 (Suppl. 8):54 (Abstract 2.72). [Google Scholar]
  42. Goa, K. L., and Sorkin, E. M. (1993). Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs46:409–427. [DOI] [PubMed] [Google Scholar]
  43. Gordey, M., Delorey, T. M., and Olsen, R. W. (1995). Topiramate modulates GABA receptor responses in xenopus oocytes expressing several recombinant receptor subunit combinations. Annual Meeting of the American Epilepsy Society, Baltimore, December 1–6, 1995. Epilepsia36 (Suppl. 4):48 (Abstract 2.55).8001508 [Google Scholar]
  44. Granneman, G. R., Schneck, D. W., Cavanaugh, J. H., and Witt, G. F. (1996). Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J. Clin. Psychiatry57:204–206. [PubMed] [Google Scholar]
  45. Grant, S. M., and Faulds, D. (1992). Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs43:873–888. [DOI] [PubMed] [Google Scholar]
  46. Graves, N. M. (1995). Neuropharmacology and drug interactions in clinical practice. Epilepsia36 (Suppl. 2):S27-S33. [DOI] [PubMed] [Google Scholar]
  47. Grimm, S. W., Stams, K. R., and Bui, K. (1997). In vitro prediction of potential metabolic drug interactions for quetiapine. 150th Annual Meeting of the American Psychiatric Association, San Diego, May 17–22, 1997, Abstract NR251, p. 135–136.
  48. Grimsley, S. R., Jann, M. W., Carter, J. G., D'Mello, A. P., and D'Souza, M. J. (1991). Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin. Pharmacol. Ther.50:10–15. [DOI] [PubMed] [Google Scholar]
  49. Hara, S., Imai, Y., Takei, S., Iwata, O., Yokoyama, N., and Ishida, T. (1993). Five cases of zonisamide-related psychosis: with particular reference to the drug interaction between zonisamide and phenytoin and to the risk factors for epileptic psychosis. Seishin Chiryougaku8:59–64 (in Japanese). [Google Scholar]
  50. Ishizaki, T., Chiba, K., Saito, M., Kobayashi, K., and Iizuka, R. (1984). The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. J. Clin. Psychopharmacol.4:254–261. [PubMed] [Google Scholar]
  51. Jann, M. W., Fidone, G. S., Hernandez, J. M., Amrung, S., and Davis, C. M. (1989). Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Res.28:153–159. [DOI] [PubMed] [Google Scholar]
  52. Jefferson, J. W., Greist, J. H., Ackerman, D. L., and Carroll, J. A. (1987). Lithium Encyclopedia for Clinical Practice, 2nd ed., American Psychiatric Press, Washington, DC. [Google Scholar]
  53. Jerling, M., Lindstrom, L., Bondesson, U., and Bertilsson, L. (1994). Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther. Drug Monit.16:368–374. [DOI] [PubMed] [Google Scholar]
  54. Jung, M. J., and Palfreyman, M. G. (1995). Vigabatrin: mechanisms of action. In Levy, R. H., Mattson, R. H., and Meldrum, B. S. (eds.), Antiepileptic Drugs, 4th ed., Raven Press, New York, pp. 903–913. [Google Scholar]
  55. Kahn, E. M., Schulz, S. C., Perel, J. M., and Alexander, J. E. (1990). Change in haloperidol level due to carbamazepine—A complicating factor in combined medication for schizophrenia. J. Clin. Psychopharmacol.10:54–57. [DOI] [PubMed] [Google Scholar]
  56. Kanba, S., Yagi, G., Kamijima, K., Suzuki, T., Tajima, O., Otaki, J., Arata, E., Koshikawa, H., Nibuya, M., Kinoshita, N., et al. (1994). The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog. Neuropsychopharmacol. Biol. Psychiatry18:707–715. [DOI] [PubMed] [Google Scholar]
  57. Kato, T., Shioiri, T., Inubushi, T., and Takahashi, S. (1993). Brain lithium concentrations measured with lithium-7 magnetic resonance spectroscopy in patients with affective disorders: Relationship to erythrocyte and serum concentrations. Biol. Psychiatry33:147–152. [DOI] [PubMed] [Google Scholar]
  58. Kato, T., Inubushi, T., and Takahashi, S. (1994). Relationship of lithium concentrations in the brain measured by lithium-7 magnetic resonance spectroscopy to treatment response in mania. J. Clin. Psychopharmacol.14:330–335. [PubMed] [Google Scholar]
  59. Kaufman, K. R. (1998). Adjunctive tiagabine treatment of psychiatric disorders: Three cases. Ann. Clin. Psychiatry10:181–184. [DOI] [PubMed] [Google Scholar]
  60. Kaufman, K. R., and Gerner, R. (1997). Lamotrigine toxicity secondary to sertraline. Annual Meeting of the American Epilepsy Society, Boston, December 7–10, 1997. Epilepsia38 (Suppl. 8):100 (Abstract 3.047). [Google Scholar]
  61. Kerr, B. M., Thummel, K. E., Wurden, C. J., Klein, S. M., Kroetz, D. L., Gonzalez, F. J., and Levy, R. H. (1994). Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol.47:1969–1979. [DOI] [PubMed] [Google Scholar]
  62. Ketter, T. A., Flockhart, D. A., Post, R. M., Denicoff, K., Pazzaglia, P. J., Marangell, L. B., George, M. S., and Callahan, A. M. (1995a). The emerging role of cytochrome P450 3A in psychopharmacology. J. Clin. Psychopharmacol.15:387–398. [DOI] [PubMed] [Google Scholar]
  63. Ketter, T. A., Jenkins, J. B., Schroeder, D. H., Pazzaglia, P. J., Marangell, L. B., George, M. S., Callahan, A. M., Hinton, M. L., Chao, J., and Post, R. M. (1995b). Carbamazepine but not valproate induces bupropion metabolism. J. Clin. Psychopharmacol.15:327–333. [DOI] [PubMed] [Google Scholar]
  64. Ketter, T. A., Malow, B. A., Flamini, R., Ko, D., White, S. R., Stertz, B. E., Post, R. M., and Theodore, W. H. (1996). Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res.23:129–137. [DOI] [PubMed] [Google Scholar]
  65. Ketter, T. A., Pazzaglia, P. J., and Post, R. M. (1992). Synergy of carbamazepine and valproic acid in affective illness: Case report and review of the literature. J. Clin. Psychopharmacol.12:276–281. [PubMed] [Google Scholar]
  66. Ketter, T. A., and Post, R. M. (1994). Clinical pharmacology and pharmacokinetics of carbamazepine. In Joffe, R. T., and Calabrese, J. R. (eds.), Anticonvulsants in Psychiatry, Marcel Dekker, New York, pp. 147–187. [Google Scholar]
  67. Ketter, T. A., Post, R. M., Parekh, P. I., and Worthington, K. (1995c). Addition of monoamine oxidase inhibitors to carbamazepine: Preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J. Clin. Psychiatry56:471–475. [PubMed] [Google Scholar]
  68. Ketter, T. A., Post, R. M., and Worthington, K. (1991a). Principles of clinically important drug interactions with carbamazepine. Part I. J. Clin. Psychopharmacol.11:198–203. [PubMed] [Google Scholar]
  69. Ketter, T. A., Post, R. M., and Worthington, K. (1991b). Principles of clinically important drug interactions with carbamazepine. Part II. J. Clin. Psychopharmacol.11:306–313. [PubMed] [Google Scholar]
  70. Klosterskov Jensen, P., Saano, V., Haring, P., Svenstrup, B., and Menge, G. P. (1992). Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia33:1149–1152. [DOI] [PubMed] [Google Scholar]
  71. Lai, A. A., Levy, R. H., and Cutler, R. E. (1978). Time-course of interaction between carbamazepine and clonazepam in normal man. Clin. Pharmacol. Ther.24:316–323. [DOI] [PubMed] [Google Scholar]
  72. Lane, H. Y., and Chang, W. H. (1998). Risperidone-carbamazepine interactions: Is cytochrome P450 3A involved? [letter] J. Clin. Psychiatry59:430–431. [PubMed] [Google Scholar]
  73. Lane, R. M. (1994). Carbamazepine and sertraline [letter]. N.Z. Med. J.107:209. [PubMed] [Google Scholar]
  74. Leach, M. J., Lees, G., and Riddall, D. R. (1995). Lamotrigine: Mechanisms of action. In Levy, R. H., Mattson, R. H., and Meldrum, B. S. (eds.), Antiepileptic Drugs, 4th ed. Raven Press, New York, pp. 861–869. [Google Scholar]
  75. Lee, D. O., Steingard, R. J., Cesena, M., Helmers, S. L., Riviello, J. J., and Mikati, M. A. (1996). Behavioral side effects of gabapentin in children. Epilepsia37:87–90. [DOI] [PubMed] [Google Scholar]
  76. Leppik, I. E. (1995a). Felbamate. Epilepsia36 (Suppl. 2):S66-S72. [DOI] [PubMed] [Google Scholar]
  77. Leppik, I. E. (1995b). Tiagabine: The safety landscape. Epilepsia36 (Suppl. 6):S10-S13. [DOI] [PubMed] [Google Scholar]
  78. Levy, R. H., Bishop, F., Streeter, A. J., Trager, W. F., Kunze, K. L., Thummel, K. T., and Mather, G. G. (1995a). Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum. Annual Meeting of the American Epilepsy Society, Baltimore, December 1–6, 1995. Epilepsia36 (Suppl. 4):47 (Abstract 2.52). [Google Scholar]
  79. Levy, R. H., Lane, E. A., Guyot, M., Brachet-Liermain, A., Cenraud, B., and Loiseau, P. (1983). Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man. Drug Metab. Dispos. Biol. Fate Chem.11:286–292. [PubMed] [Google Scholar]
  80. Levy, R. H., Mattson, R. H., and Meldrum, B. S. (1995b). Antiepileptic Drugs, 4th ed., Raven Press, New York. [Google Scholar]
  81. Levy, R. H., Morselli, P. L., Bianchetti, G., Guyot, M., Brachet-Liermain, A., and Loiseau, P. (1982). Interaction between valproic acid and carbamazepine in epileptic patients. In Levy, R. H., Pitlick, W. H., Eichelbaum, M., et al. (eds.), Metabolism of Antiepileptic Drugs, Raven Press, New York, pp. 45–51. [Google Scholar]
  82. Levy, R. H., Trager, W. F., Kunze, K. L., Thummel, K., Wienkers, L., Bishop, F., Bajpai, M., and Mather, G. G. (1994). Prediction of phenytoin interactions based on cytochrome P450 isoforms. Annual Meeting of the American Epilepsy Society, New Orleans, December 2–8, 1994. Epilepsia35(Suppl. 8):143 (Abstract L.05). [Google Scholar]
  83. Lloyd, K. G., Zivkovic, B., Scatton, B., Morselli, P. L., and Bartholini, G. (1989). The gabaergic hypothesis of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry13:341–351. [DOI] [PubMed] [Google Scholar]
  84. Macdonald, R. L., and Kelly, K. M. (1995). Antiepileptic drug mechanisms of action. Epilepsia36(Suppl. 2):S2-S12. [DOI] [PubMed] [Google Scholar]
  85. Manji, H. K., Potter, W. Z., and Lenox, R. H. (1995). Signal transduction pathways. Molecular targets for lithium's actions. Arch. Gen. Psychiatry52:531–543. [DOI] [PubMed] [Google Scholar]
  86. Marcotte, D. (1998). Use of topiramate, a new anti-epileptic as a mood stabilizer. J. Affect Disord.50:245–251. [DOI] [PubMed] [Google Scholar]
  87. Marcotte, D. B., Fogleman, L., Wolfe, N., and Nemire, R. (1997). Gabapentin: an effective therapy for patients with bipolar affective disorder. 150th Annual Meeting of the American Psychiatric Association, San Diego, May 17–22, 1997. Abstract NR261, p. 138.
  88. Matsumoto, K., Miyazaki, H., Fujii, T., and Hashimoto, M. (1989). Binding of sulfonamides to erythrocytes and their components. Chem. Pharm. Bull. (Tokyo)37:1913–5. [DOI] [PubMed] [Google Scholar]
  89. McConnell, H., Snyder, P. J., Duffy, J. D., Weilburg, J., Valeriano, J., Brillman, J., Cress, K., and Cavalier, J. (1996). Neuropsychiatric side effects related to treatment with felbamate. J. Neuropsychiatry Clin. Neurosci.8:341–346. [DOI] [PubMed] [Google Scholar]
  90. McElroy, S. L., Keck, P. E., Stanton, S. P., Tugrul, K. C., Bennett, J. A., and Strakowski, S. M. (1996). A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J. Clin. Psychiatry57:142–6. [PubMed] [Google Scholar]
  91. McElroy, S. L., Soutullo, C. A., Keck, P. E., Jr., and Kmetz, G. F. (1997). A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann. Clin. Psychiatry9:99. [DOI] [PubMed] [Google Scholar]
  92. Mesdjian, E., Dravet, C., Cenraud, B., and Roger, J. (1980). Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia21:489–496. [DOI] [PubMed] [Google Scholar]
  93. Palmer, K. J., and McTavish, D. (1993). Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs45:1041–1065. [DOI] [PubMed] [Google Scholar]
  94. Pande, A. C., Davidson, J. R. T., Greist, J. H., Jefferson, J. W., Weisler, R., and Sutherland, S. (1997). A placebo-controlled study of gabapentin in social phobia. 36th Annual Meeting of the American College of Neuropsychopharmacology, Waikola, Hawaii, December 8–12, 1997. Abstract. p. 141.
  95. Pennell, P. B., Ogaily, M. S., and Macdonald, R. L. (1995). Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology45:456–460. [DOI] [PubMed] [Google Scholar]
  96. Peters, D. H., and Sorkin, E. M. (1993). Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs45:760–787. [DOI] [PubMed] [Google Scholar]
  97. Petroff, O. A., Rothman, D. L., Behar, K. L., and Mattson, R. H. (1995). Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of gamma-aminobutyric acid, glutamate, and glutamine in human brain. Epilepsia36:457–464. [DOI] [PubMed] [Google Scholar]
  98. Petty, F. (1995). GABA and mood disorders: A brief review and hypothesis. J. Affect. Disord.34:275–281. [DOI] [PubMed] [Google Scholar]
  99. Pitterle, M. E., and Collins, D. M. (1988). Carbamazepine–10–11-epoxide evaluation associated with coadministration of loxapine or amoxapine. Epilepsia29:654 (abstract;). [Google Scholar]
  100. Post, R. M., Weiss, S. R. B., Chuang, D. M., and Ketter, T. A. (1994). Mechanisms of action of carbamazepine in seizure and affective disorders. In Joffe, R. T., and Calabrese, J. R. (eds.), Anticonvulsants in Psychiatry, Marcel Dekker, New York, pp. 43–92. [Google Scholar]
  101. Potter, W. Z., and Ketter, T. A. (1993). Pharmacological issues in the treatment of bipolar disorder: Focus on mood-stabilizing compounds. Can. J. Psychiatry38:S51-S516. [PubMed] [Google Scholar]
  102. Price, W. A., and DiMarzio, L. R. (1988). Verapamil-carbamazepine neurotoxicity [letter]. J. Clin. Psychiatry49:80. [PubMed] [Google Scholar]
  103. Rambeck, B., and Wolf, P. (1993). Lamotrigine clinical pharmacokinetics. Clin. Pharmacokinet.25:433–443. [DOI] [PubMed] [Google Scholar]
  104. Redington, K., Wells, C., and Petito, F. (1992). Erythromycin and valproate interaction [letter]. Ann. Intern. Med.116:877–887. [DOI] [PubMed] [Google Scholar]
  105. Rey, E., Pons, G., and Olive, G. (1992). Vigabatrin. Clinical pharmacokinetics. Clin. Pharmacokinet.23:267–278. [DOI] [PubMed] [Google Scholar]
  106. Richens, A. (1993). Clinical pharmacokinetics of gabapentin. In Chadwick, D. (ed.), New Trends in Epilepsy Management: The Role of Gabapentin, Royal Society of Medicine Services, London, pp. 41–46. [Google Scholar]
  107. Ring, H. A., Crellin, R., Kirker, S., and Reynolds, E. H. (1993). Vigabatrin and depression. J. Neurol. Neurosurg. Psychiatry56:925–928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Ryback, R. S., Brodsky, L., and Munasifi, F. (1997). Gabapentin in bipolar disorder [letter]. J. Neuropsychiatry Clin. Neurosci.9:301. [DOI] [PubMed] [Google Scholar]
  109. Sachdeo, R. C., Sachdeo, S. K., Walker, S. A., Kramer, L. D., Nayak, R. K., and Doose, D. R. (1996). Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia37:774–780. [DOI] [PubMed] [Google Scholar]
  110. Sackellares, J. C., Sato, S., Dreifuss, F. E., and Penry, J. K. (1981). Reduction of steady-state valproate levels by other antiepileptic drugs. Epilepsia22:437–441. [DOI] [PubMed] [Google Scholar]
  111. Sander, J. W., Hart, Y. M., Trimble, M. R., and Shorvon, S. D. (1991). Vigabatrin and psychosis. J. Neurol. Neurosurg. Psychiatry54:435–439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Sayin, U., Purali, N., Ozkan, T., Altug, T., and Buyukdevrim, S. (1992). Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav.43:529–535. [DOI] [PubMed] [Google Scholar]
  113. Schaffer, C., and Schaffer, L. (1996). Gabapentin for bipolar disorder. Curr. Affect. Illness15:2–3. [Google Scholar]
  114. Schaffer, C. B., and Schaffer, L. C. (1997). Gabapentin in the treatment of bipolar disorder [letter]. Am. J. Psychiatry154:291–292. [DOI] [PubMed] [Google Scholar]
  115. Severt, L., Coulter, D. A., Sombati, S., and DeLorenzo, R. J. (1995). Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Annual Meeting of the American Epilepsy Society, Baltimore, December 1–6, 1995. Epilepsia36(Suppl. 4):38 (Abstract 2.16). [Google Scholar]
  116. Shank, R. P., Gardocki, J. F., Vaught, J. L., Davis, C. B., Schupsky, J. J., Raffa, R. B., Dodgson, S. J., Nortey, S. O., and Maryanoff, B. E. (1994). Topiramate: Preclinical evaluation of structurally novel anticonvulsant. Epilepsia35:450–460. [DOI] [PubMed] [Google Scholar]
  117. Shorvon, S. D. (1996). Safety of topiramate: Adverse events and relationships to dosing. Epilepsia37(Suppl. 2):S18-S22. [DOI] [PubMed] [Google Scholar]
  118. Sombati, S., Coulter, D. A., and DeLorenzo, R. J. (1995). Effects of topiramate on sustained repetitive firing and low Mg2+-induced seizure discharges in cultured hippocampal neurons. Annual Meeting of the American Epilepsy Society, Baltimore, December 1–6, 1995. Epilepsia36(Suppl. 4):38 (Abstract 2.15). [Google Scholar]
  119. Sovner, R., and Davis, J. M. (1991). A potential drug interaction between fluoxetine and valproic acid [letter]. J. Clin. Psychopharmacol.11:389. [DOI] [PubMed] [Google Scholar]
  120. Sporn, J., and Sachs, G. (1997). The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J. Clin. Psychopharmacol.17:185–189. [DOI] [PubMed] [Google Scholar]
  121. Steketee, R. W., Wassilak, S. G., Adkins, W. N., Jr., Burstyn, D. G., Manclark, C. R., Berg, J., Hopfensperger, D., Schell, W. L., and Davis, J. P. (1988). Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. J. Infect. Dis.157:434–440. [DOI] [PubMed] [Google Scholar]
  122. Stewart, B. H., Kugler, A. R., Thompson, P. R., and Bockbrader, H. N. (1993). A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res.10:276–281. [DOI] [PubMed] [Google Scholar]
  123. Suppes, T., Brown, E. S., McElroy, S. L., Kmetz, G. F., Frye, M., Keck, P. E., Kupka, R., Altshuler, L., Rochussen, J., Haytef, J., Leverich, G. S., and Post, R. (1998). A pilot trial of adjunctive topiramate in the treatment of bipolar disorder: application of the Stanley Foundation Bipolar Network (SFBN) prospective protocol. 37th Annual Meeting of the American College of Neuropsychopharmacology, Los Croabas, Puerto Rico, December 14–18, 1998. Abstract. p. 306.
  124. Suzdak, P. D., and Jansen, J. A. (1995). A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia36:612–626. [DOI] [PubMed] [Google Scholar]
  125. Tartara, A., Galimberti, C. A., Manni, R., Parietti, L., Zucca, C., Baasch, H., Caresia, L., Muck, W., Barzaghi, N., Gatti, G., and Perucca, E. (1991). Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br. J. Clin. Pharmacol.32:335–340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Taylor, C. P. (1995). Gabapentin: Mechanisms of action. In Levy, R. H., Mattson, R. H., and Meldrum, B. S. (eds.), Antiepileptic Drugs, 4th ed., Raven Press, New York, pp. 829–841. [Google Scholar]
  127. Thakker, K. M., Mangat, S., Garnett, W. R., Levy, R. H., and Kochak, G. M. (1992). Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients. Biopharm. Drug. Disp.13:559–569. [DOI] [PubMed] [Google Scholar]
  128. Wagner, M. L., Graves, N. M., Leppik, I. E., Remmel, R. P., Ward, D. L., and Shumaker, R. C. (1991). Effect of felbamate on valproate disposition. Epilepsia32:15 (abstract). [Google Scholar]
  129. Waldmeier, P. C., Baumann, P. A., Wicki, P., Feldtrauer, J. J., Stierlin, C., and Schmutz, M. (1995). Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology45:1907–1913. [DOI] [PubMed] [Google Scholar]
  130. Webster, L. K., Mihaly, G. W., Jones, D. B., Smallwood, R. A., Phillips, J. A., and Vajda, F. J. (1984). Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur. J. Clin. Pharmacol.27:341–343. [DOI] [PubMed] [Google Scholar]
  131. Winsberg, M. E., DeGolia, S. G., Strong, C. M., and Ketter, T. A. (1997). Divalproex in medication-naive bipolar II depression. 150th Annual Meeting of the American Psychiatric Association, San Diego, May 17–22, 1997. Abstract NR113, p. 97.
  132. Wright, J. M., Stokes, E. F., and Sweeney, V. P. (1982). Isoniazid-induced carbamazepine toxicity and vice versa: A double drug interaction. N. Engl. J. Med.307:1325–1327. [DOI] [PubMed] [Google Scholar]
  133. Wrighton, S. A., and Stevens, J. C. (1992). The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol.22:1–21. [DOI] [PubMed] [Google Scholar]
  134. Young, L. T., Robb, J. C., Patelis-Siotis, I., MacDonald, C., and Joffe, R. T. (1997). Acute treatment of bipolar depression with gabapentin. Biol. Psychiatry42:851–853. [DOI] [PubMed] [Google Scholar]

Articles from Cellular and Molecular Neurobiology are provided here courtesy of Springer

RESOURCES